CtDNA 양성이거나 고위험 병리학적 특징을 갖고 있는 1기 선암종 NSCLC 참가자를 대상으로 완전한 종양 절제 후 표준 치료와 Rilvegostomig 또는 Rilvegostomig 단독요법과 병용한 보조제 Dato-DXd의 무작위 배정 제3상 연구 (TROPION-Lung12)
1기 선암종 비소세포폐암 참가자를 대상으로 완전 종양 절제 후 보조제 Datopotamab Deruxtecan(Dato-DXd)과 Rilvegostomig 또는 Rilvegostomig 단독요법과 표준 치료를 비교한 제3상 무작위 공개 라벨 글로벌 연구 ctDNA 양성이거나 고위험 병리학적 특징을 가진 사람(TROPION-Lung12)
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The primary objective of the study is to assess the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig relative to SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Kaohsiung City, 대만, 80756
- Research Site
-
Taipei, 대만, 10002
- Research Site
-
Taipei, 대만, 112
- Research Site
-
Taipei, 대만, 114
- Research Site
-
Taoyuan, 대만, 333
- Research Site
-
-
-
-
-
Kuala Lumpur, 말레이시아, 59100
- Research Site
-
Kuala Lumpur, 말레이시아, 50586
- Research Site
-
Kuching, 말레이시아, 93586
- Research Site
-
-
-
-
Arizona
-
Tucson, Arizona, 미국, 85724
- Research Site
-
-
California
-
Duarte, California, 미국, 91010
- Research Site
-
Glendale, California, 미국, 91204
- Research Site
-
Los Angeles, California, 미국, 90089
- Research Site
-
-
Colorado
-
Lone Tree, Colorado, 미국, 80124
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20007
- Research Site
-
-
Florida
-
Jacksonville, Florida, 미국, 32224
- Research Site
-
St. Petersburg, Florida, 미국, 33709
- Research Site
-
-
Illinois
-
Chicago, Illinois, 미국, 60637
- Research Site
-
Evanston, Illinois, 미국, 60201
- Research Site
-
Zion, Illinois, 미국, 60099
- Research Site
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40503
- Research Site
-
-
Maryland
-
Baltimore, Maryland, 미국, 21237
- Research Site
-
-
Michigan
-
Farmington Hills, Michigan, 미국, 48334
- Research Site
-
Grand Rapids, Michigan, 미국, 49503
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55407
- Research Site
-
-
Montana
-
Billings, Montana, 미국, 59102
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68130
- Research Site
-
-
New York
-
East Syracuse, New York, 미국, 13057
- Research Site
-
Mineola, New York, 미국, 11501
- Research Site
-
New York, New York, 미국, 10016
- Research Site
-
New York, New York, 미국, 10065
- Research Site
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- Research Site
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, 미국, 18015
- Research Site
-
Philadelphia, Pennsylvania, 미국, 19107
- Research Site
-
Pittsburgh, Pennsylvania, 미국, 15212
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, 미국, 37920
- Research Site
-
Memphis, Tennessee, 미국, 38120
- Research Site
-
Nashville, Tennessee, 미국, 37203
- Research Site
-
-
Texas
-
Austin, Texas, 미국, 78745
- Research Site
-
Dallas, Texas, 미국, 75231
- Research Site
-
Houston, Texas, 미국, 77030
- Research Site
-
San Antonio, Texas, 미국, 78217
- Research Site
-
-
Virginia
-
Fairfax, Virginia, 미국, 22031
- Research Site
-
-
Washington
-
Seattle, Washington, 미국, 98104
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, 미국, 53792
- Research Site
-
-
-
-
-
Hanoi, 베트남, 100000
- Research Site
-
Ho Chi Minh City, 베트남, 700000
- Research Site
-
Hà Nội, 베트남, 100000
- Research Site
-
Vinh, 베트남, 460000
- Research Site
-
-
-
-
-
Barretos, 브라질, 14784-057
- Research Site
-
Brasília, 브라질, 70200-730
- Research Site
-
Florianópolis, 브라질, 88034-000
- Research Site
-
São Paulo, 브라질, 01323-903
- Research Site
-
Teresina, 브라질, 64049-200
- Research Site
-
-
-
-
-
Bunkyō City, 일본, 113-8603
- Research Site
-
Chiba, 일본, 260-0877
- Research Site
-
Chūōku, 일본, 104-0045
- Research Site
-
Fukuoka, 일본, 812-8582
- Research Site
-
Hidaka-shi, 일본, 350-1298
- Research Site
-
Hiroshima, 일본, 734-8551
- Research Site
-
Hiroshima, 일본, 730-8518
- Research Site
-
Iwakuni-shi, 일본, 740-8510
- Research Site
-
Kashiwa, 일본, 277-8577
- Research Site
-
Kitaadachi-gun, 일본, 362-0806
- Research Site
-
Kobe, 일본, 650-0017
- Research Site
-
Kumamoto, 일본, 860-8556
- Research Site
-
Kōtoku, 일본, 135-8550
- Research Site
-
Nagoya, 일본, 464-8681
- Research Site
-
Niigata, 일본, 951-8566
- Research Site
-
Osakasayama-shi, 일본, 589-8511
- Research Site
-
Sapporo, 일본, 003-0804
- Research Site
-
Sendai, 일본, 980-8574
- Research Site
-
Sendai, 일본, 980-0873
- Research Site
-
Wakayama, 일본, 641-8510
- Research Site
-
Yokohama, 일본, 241-8515
- Research Site
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, 캐나다, B3H 2Y9
- Research Site
-
-
Ontario
-
Oshawa, Ontario, 캐나다, L1G 2B9
- Research Site
-
-
Quebec
-
Montreal, Quebec, 캐나다, H2X 3J4
- Research Site
-
-
-
-
-
Bangkok, 태국, 10400
- Research Site
-
Bangkoknoi, 태국, 10700
- Research Site
-
Banphaeo, 태국, 74120
- Research Site
-
Dusit, 태국, 10300
- Research Site
-
Hat Yai, 태국, 90110
- Research Site
-
Muang, 태국, 50200
- Research Site
-
Muang, 태국, 40002
- Research Site
-
Ratchathewi, 태국, 10400
- Research Site
-
-
-
-
-
Ankara, 터키 (Türkiye), 06280
- Research Site
-
Ankara, 터키 (Türkiye), 06010
- Research Site
-
Mersin, 터키 (Türkiye), 33240
- Research Site
-
-
-
-
-
Hong Kong, 홍콩, 999077
- Research Site
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Histologically documented treatment-naive Stage I (T < 4 cm, AJCC 8th ed) adenocarcinoma NSCLC
- Complete surgical resection (R0) of the primary NSCLC
- Unequivocal no evidence of disease at post-surgical
- Pre-surgical ctDNA-positive result (Stage IA or IB) OR presence of at least one high-risk pathological feature (visceral pleural invasion (VPI), lymphovascular invasion (LVI), high-grade histology) (Stage IB only)
- ECOG of 0 or 1, life expectancy of > 6 months and complete recovery after surgery
- Adequate bone marrow reserve and organ function
Exclusion Criteria:
- Sensitizing EGFR mutation and/or ALK alteration
- History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
- Significant pulmonary function compromise
- History of another primary malignancy within 3 years (with exceptions)
- Any evidence of severe or uncontrolled systemic diseases, including but not limited to bleeding diseases, active infection and cardiac disease
- Active or prior documented autoimmune or inflammatory disorders (with exceptions)
- Active infection with tuberculosis, hepatitis B or C virus, hepatitis A, or known HIV infection that is not well controlled
- History of active primary immunodeficiency
- Clinically significant corneal disease
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Dato-DXd + rilvegostomig
Participants in the Dato-DXd in combination with rilvegostomig group will receive Dato-DXd and rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W). |
Datopotamab Deruxtecan IV (intravenous)
다른 이름들:
Rilvegostomig IV (intravenous)
다른 이름들:
|
|
실험적: Rilvegostomig
Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W). |
Rilvegostomig IV (intravenous)
다른 이름들:
|
|
활성 비교기: Standard of Care (SoC)
Patients in SoC group will undergo observation or will receive Investigator's Choice of Chemotherapy (ICC). |
Carboplatin IV (intravenous), Active Comparator Cisplatin IV (intravenous), Active Comparator Etoposide IV (intravenous), Active Comparator Pemetrexed IV (intravenous), Active Comparator Vinorelbine IV (intravenous), Active Comparator UFT Oral route of administration, Active Comparator |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Disease-Free Survival (DFS) using BICR in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
기간: From date of randomisation up to approximately 10 years.
|
The analysis will include all randomised participants as randomised. All events will be included, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy. The measure of interest is the HR of DFS. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
From date of randomisation up to approximately 10 years.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Survival (OS) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
기간: From date of randomisation up to approximately 10 years.
|
The analysis will include all randomised participants as randomised. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy. The measure of interest is the HR of OS. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
From date of randomisation up to approximately 10 years.
|
|
Participant-reported physical function in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
기간: Measured at weeks 12, 24 and 48.
|
The analysis will include all randomised participants as randomised. The physical function will be measured by the PROMIS SF PF 8c. Data from PROMIS SF PF 8c will capture participants' perceived ability to perform specific activities from daily life and will be scored on a 5-point rating scale. The measure of interest will be the between treatment group difference in adjusted mean in physical function scores. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
Measured at weeks 12, 24 and 48.
|
|
Participant-reported GHS/QoL in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
기간: Measured at weeks 12, 24 and 48.
|
The analysis will include all randomised participants as randomised. The GHS/QoL scores will be measured by the GHS/QoL scale from EORTC IL172. The measure of interest will be the between treatment group difference in adjusted mean in GHS/QoL scores. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
Measured at weeks 12, 24 and 48.
|
|
Pharmacokinetics (PK)
기간: Up to 30 or 90 days post-last dose of study intervention.
|
Concentration of Dato-DXd, total anti-TROP2 antibody, and MAAA-1181a (payload deruxtecan) in plasma or serum. |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Pharmacokinetics (PK)
기간: Up to 30 or 90 days post-last dose of study intervention.
|
Concentration of rilvegostomig in plasma or serum. |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Pharmacokinetics (PK)
기간: Up to 30 or 90 days post-last dose of study intervention.
|
PK parameters (peak and through concentrations). |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Immunogenicity
기간: Up to 30 or 90 days post-last dose of study intervention.
|
Presence of ADAs for Dato-DXd and rilvegostomig (confirmatory results: titres and neutralising antibodies for confirmed positive samples). |
Up to 30 or 90 days post-last dose of study intervention.
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: David Jones, MD, Memorial Sloan Kettering Cancer Center, New York, United States of America
- 수석 연구원: Enriqueta Felip, MD, Vall d'Hebron Hospital, Barcelona, Spain
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
- 부위별 신생물
- 신생물
- 호흡기 질환
- 조직학적 유형에 따른 신생물
- 폐 질환
- 신생물, 선상 및 상피
- 호흡기 신생물
- 흉부 신생물
- 폐 신생물
- 암종
- 기관지 암종
- 기관지 신생물
- 암종, 비소세포폐
- 선암종
- 아미노산, 펩티드 및 단백질
- 유기 화학 물질
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 탄화수소
- 탄화수소, 순환
- 탄수화물
- 알칼로이드
- Podophyllotoxin
- 테트라 하이드로 나프탈렌
- 나프탈렌
- 다 환식 방향족 탄화수소
- 탄화수소, 방향족
- 다 환식 화합물
- 글루코 시드
- 글리코 사이드
- 인돌
- 무기 화학 물질
- 염소 화합물
- 질소 화합물
- 조정 복합체
- 구아닌
- Hypoxanthines
- 푸리 논
- 퓨린
- 글루타메이트
- 아미노산, 산성
- 아미노산
- 아미노산, 디카 르 복실
- Vinca 알칼로이드
- Secologanin Tryptamine 알칼로이드
- 인돌 알칼로이드
- 인돌리 지딘
- 인도인
- 백금 화합물
- 비노렐빈
- 페메트렉시드
- 에토포시드
- 카르보플라틴
- 시스플라틴
기타 연구 ID 번호
기타 연구 ID 번호
- D926TC00001
- 2024-512195-35-00 (레지스트리 식별자: CTIS)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 공유 기간
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 공유 액세스 기준
When a request has been approved, AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool.
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .